Laurus Labs Stock Up by More Than 6% Today

Mumbai, July 28, 2025 – Laurus Labs stock is gaining today. At 1:50 p.m. IST, 28th July, 2025, the stock is up by 6.70% at Rs 893.90. This gain follows the news that Andhra Pradesh government has alloted 531 acres of land to the company for setting up a pharma zone.

Stock Performance Snapshot

As of 1:30 PM, the share price of Laurus Labs traded at ₹892.05, representing a 6.48% increase from its previous close of ₹837.75. The share traded between 901.50 and 828.05 today (high and low range), reaching its highest point of the 52 weeks.

Trigger: ₹5,630 Cr Pharma Zone Project

The surge follows Laurus Labs’ announcement that it has acquired 531.77 acres of land from the Government of Andhra Pradesh at Rambilli (IP Phase-II, Anakapalli District) for a new Laurus Pharma Zone (LPZ). The project involves a phased investment of ₹5,630 crore and is expected to create 6,350 jobs over a period of eight years.

Investor Sentiment and Technicals

At midday, the stock was favorable, revealing over 5.99 lakh buy orders against 4.57 lakh sell orders, contributing to a favorable demand-supply situation. The company has a P/E ratio of 89.82, indicating expectations of high growth in the pharma manufacturing vertical.

Market participants highlighted the size of the expansion and job creation potential, which solidified Laurus Labs’ growth runway in formulations and APIs.

About the Company

Laurus Labs Ltd. is a Hyderabad‑based, research‑driven pharmaceutical and biotech company that develops and manufactures generic Active Pharmaceutical Ingredients (APIs), notably in anti‑retroviral, oncology, cardiovascular, and gastro‑therapeutic segments, and finished dosage formulations (FDF) for global markets.

Disclaimer:  At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations